Advertisement
Singapore markets closed

  • Straits Times Index

    3,280.10
    -7.65 (-0.23%)
     

  • Nikkei

    37,934.76
    +306.28 (+0.81%)
     

  • Hang Seng

    17,651.15
    +366.61 (+2.12%)
     

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • Bitcoin USD

    63,625.71
    -511.85 (-0.80%)
     

  • CMC Crypto 200

    1,383.71
    -12.82 (-0.96%)
     

  • S&P 500

    5,104.54
    +56.12 (+1.11%)
     

  • Dow

    38,257.52
    +171.72 (+0.45%)
     

  • Nasdaq

    15,935.91
    +324.15 (+2.08%)
     

  • Gold

    2,349.40
    +6.90 (+0.29%)
     

  • Crude Oil

    84.05
    +0.48 (+0.57%)
     

  • 10-Yr Bond

    4.6750
    -0.0310 (-0.66%)
     

  • FTSE Bursa Malaysia

    1,575.16
    +5.91 (+0.38%)
     

  • Jakarta Composite Index

    7,036.08
    -119.22 (-1.67%)
     

  • PSE Index

    6,628.75
    +53.87 (+0.82%)
     

Is a Surprise Coming for Amneal (AMRX) This Earnings Season?

Zacks Equity Research
·2-min read

Investors are always looking for stocks that are poised to beat at earnings season and Amneal Pharmaceuticals, Inc. AMRX may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Amneal is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for AMRX in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at 10 cents per share for AMRX, compared to a broader Zacks Consensus Estimate of 8 cents per share. This suggests that analysts have very recently bumped up their estimates for AMRX, giving the stock a Zacks Earnings ESP of +14.00% heading into earnings season.

AMNEAL PHARMACEUTICALS INC Price and EPS Surprise

AMNEAL PHARMACEUTICALS INC Price and EPS Surprise
AMNEAL PHARMACEUTICALS INC Price and EPS Surprise

AMNEAL PHARMACEUTICALS INC price-eps-surprise | AMNEAL PHARMACEUTICALS INC Quote

ADVERTISEMENT

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that AMRX has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Clearly, recent earnings estimate revisions suggest that good things are ahead for Amneal, and that a beat might be in the cards for the upcoming report.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AMNEAL PHARMACEUTICALS INC (AMRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research